Related by context. All words. (Click for frequent words.) 72 nadir CD4 cell 69 lymphocyte count 68 CD4 + cell 66 median CD4 65 neutrophil count 64 baseline CD4 62 leukocytosis 61 neutrophil counts 61 CD4 + 60 cells μL 60 leukocyte count 60 paraprotein 60 erythrocyte sedimentation rate 60 microvessel density 59 plasma leptin 59 serum aminotransferase levels 59 serum cortisol 59 lymphocyte counts 59 HOMA IR 58 serum urate 58 triglyceride concentrations 58 albumin excretion 58 intact parathyroid hormone 58 baseline LDH 58 serum creatinine levels 58 serum testosterone 58 transaminase levels 58 baseline CD4 + 57 PASI scores 57 serum concentrations 57 albumin excretion rate 57 MMSE score 57 cranial irradiation 57 serum PTH 57 CD# upregulation 57 HBeAg seroconversion 57 colorectal tumor 57 HbA 1c levels 57 serum PSA 57 HbA1C levels 57 hemoglobin concentration 57 serum lipid levels 57 lumbar spine BMD 57 pCR 57 serum albumin 57 lactate dehydrogenase 57 serum IgE 57 serum HCV RNA 56 antibody titer 56 tipranavir r 56 atheroma volume 56 lactate dehydrogenase LDH 56 normalize platelet 56 eosinophil count 56 liver histology 56 carotid plaque 56 PSADT 56 HER2 expression 56 Viral load 56 plasma triglycerides 56 serum phosphate levels 56 doxorubicin docetaxel 56 serum bicarbonate 56 inflammatory biomarkers 56 hemoglobin A1c levels 56 thyroid stimulating hormone 56 pmol L 56 HBV DNA levels 56 platelet reactivity 56 plasma folate 56 viral titers 56 haematological toxicity 56 T2 lesions 56 mmHg diastolic 56 serum BDNF 56 urine albumin 56 serum calcium levels 56 LDB CPR 56 mcL 56 serum sodium levels 56 Hb A1C 56 glycosylated hemoglobin HbA1c 56 viral titer 56 PSA nadir 56 histologic subtype 56 lymphocytosis 56 neurocognitive function 56 deep venous thromboses 55 QTcF 55 glycated hemoglobin levels 55 aspartate aminotransferase 55 pT3 55 serum CRP 55 dose Iluvien 55 creatinine ratio 55 CD4 T 55 afterload 55 specific antigen PSA 55 serum antibody 55 HAQ DI 55 #.#ng/ml 55 granulocyte 55 posttreatment 55 macrophage infiltration 55 postoperative morbidity 55 plasma cortisol 55 hemoglobin A1c HbA1c 55 serum urate levels 55 alanine aminotransferase 55 undetectable viral 55 colorectal adenoma 55 T2 lesion volume 55 cells mcL 55 univariate analysis 55 serum prostate 55 fructosamine 55 blood Phe 55 hemoglobin Hb 55 antiandrogen 55 homocysteine concentrations 55 CD4 cell 55 hepatic insulin sensitivity 55 hematologic toxicity 55 CRp 55 euthyroid 55 serum LDL cholesterol 55 blood Phe levels 55 del 5q MDS 55 plasma renin activity 55 serum HBV DNA 55 serum testosterone levels 55 Serum creatinine 54 alanine aminotransferase ALT 54 autoantibody levels 54 confidence intervals CIs 54 octreotide LAR 54 bioavailable testosterone 54 hip BMD 54 serum phosphate 54 experienced virologic failure 54 serum IgG 54 mIU ml 54 definite stent thrombosis 54 CDAI 54 acromegalic patients 54 tissue oxygenation 54 endometrial thickness 54 CD4 + cells 54 anagrelide 54 triacylglycerol concentrations 54 Insulin sensitivity 54 serum potassium 54 DAS# [002] 54 μg d 54 logistic regression analysis 54 inflammatory lesions 54 #mmHg [001] 54 aspartate aminotransferase AST 54 salmeterol fluticasone propionate 54 CD4 + T 54 HIV RNA 54 corticosteroid dose 54 log# copies mL 54 adenoma recurrence 54 mg/m2 dose 54 adjuvant cisplatin 54 parasitaemia 54 timepoints 54 attain statistical significance 54 LV ejection fraction 54 urinary excretion 54 RBC transfusions 54 recurrent VTE 54 μg liter 54 CLA supplementation 54 postoperative mortality 54 μg ml 54 anti HBs 54 Platelet counts 54 binary restenosis 54 serum homocysteine 54 EDSS score 54 troponin T 54 radiosensitivity 54 baseline HbA1c 54 pg ml 54 cells/mm3 54 μmol L 54 anemia hemoglobin 54 clinically meaningful improvement 53 Inhibin B 53 intracranial hemorrhage ICH 53 eculizumab therapy 53 antigen PSA levels 53 fasting glucose levels 53 P = .# 53 morphometric vertebral fractures 53 extracapsular extension 53 TPV r 53 remission CR 53 hepatic enzymes 53 biochemical relapse 53 virologic response 53 dietary carbohydrate 53 CsA 53 steroid dexamethasone 53 virological suppression 53 intramuscular dose 53 flutamide 53 leucopenia 53 corticosterone levels 53 serum uric acid 53 relapsed MM 53 #.#/#.# mmHg [001] 53 Ishak fibrosis score 53 PASI score 53 serum potassium levels 53 mL/min/#.# m 2 53 splenectomized patients 53 HCV viral 53 medication nonadherence 53 MMSE scores 53 moderate renal impairment 53 virologic suppression 53 Retreatment 53 glycosylated hemoglobin 53 Durezol 53 fasting insulin 53 posttransplant 53 Breslow thickness 53 metabolic parameters 53 BMI z 53 HSCT 53 antiangiogenic therapy 53 Poisson regression 53 Crohn Disease Activity 53 β blockers 53 serum triglycerides 53 EDSS scores 53 serum vitamin D 53 univariate analyzes 53 hydroxyvitamin D levels 53 urinary cadmium 53 poor metabolizers 53 ventricular enlargement 53 iPTH 53 6MWD 53 virologic response EVR 53 serum IGF 53 AST ALT 53 daily subcutaneous injections 53 complete cytogenetic response 53 KRAS mutations occur 53 intermittent dosing 53 systolic dysfunction 53 rFSH 53 hematologic parameters 53 ALT elevations 53 diastolic pressures 53 nonfasting triglyceride levels 53 RBP4 levels 53 operable breast cancer 53 myocardial reperfusion 53 % CI #.#-#.# [003] 53 umol L 53 normal ULN 53 GI bleeds 52 cells uL 52 oxycodone CR 52 hepatorenal syndrome 52 hemoglobin concentrations 52 REYATAZ r arm 52 HBsAg 52 evaluable subjects 52 hemoglobin A1C 52 mRNA expression 52 QTc prolongation 52 mutated K ras 52 estimated glomerular filtration 52 glycosylated hemoglobin levels 52 Calcium intake 52 dose cohort 52 undetectable HBV DNA 52 adenoma detection 52 methylmalonic acid 52 CDAI score 52 serum phosphorus levels 52 ertapenem 52 carotid IMT 52 mcg doses 52 fractional anisotropy 52 conditional logistic regression 52 CR nPR 52 highest tertile 52 ADCS ADL 52 serum lipid 52 cardiac repolarization 52 transferrin saturation 52 blood glucose concentrations 52 absolute neutrophil count 52 triiodothyronine 52 RSV hospitalizations 52 D dimer 52 concomitant medications 52 mm3 52 genotypic resistance 52 low expressors 52 seropositivity 52 glycated hemoglobin HbA1c 52 leukopenia 52 #OHD levels 52 HCV replicon 52 Hgb 52 serum phosphorus 52 serum calcium 52 docetaxel pretreated 52 thyroglobulin 52 adiponectin concentrations 52 SGPT 52 CCyR 52 plasma homocysteine levels 52 multivariate analyzes 52 pharmacodynamic effects 52 symptomatic intracranial hemorrhage 52 plasma HCV RNA 52 circulating endothelial progenitor cells 52 HbA1C 52 CI #.#-#.# [001] 52 biochemical recurrence 52 elevated transaminases 52 parous women 52 pulmonary capillary wedge 52 microg 52 HBeAg 52 NPH insulin 52 CIN3 52 intravascular hemolysis 52 sUA levels 52 CHD mortality 52 microbiologically evaluable 52 myeloperoxidase 52 Pred Forte 52 hippocampal volume 52 foveal thickness 52 neutropenic 52 tracer uptake 52 lowest tertile 52 viremia 52 serum cholesterol 52 spirometric 52 nanomolar 52 folate concentrations 52 prospectively defined 52 creatinine levels 52 piperacillin tazobactam 52 severe neutropenia 52 Score DAS# 52 N telopeptide 52 serum sodium 52 serum parathyroid hormone 52 metabolite concentrations 52 mm ³ 52 SCr 52 liver transplant recipients 52 mL/min/#.# m2 52 LHRH agonists 52 hours postdose 52 underwent surgical resection 51 gauge vitrectomy 51 antibody titres 51 immuno suppression 51 T2DM 51 serum clusterin levels 51 sUA 51 IFN alfa 51 â ‰ ¥ 51 growth hormone secretion 51 pretreatment serum 51 postintervention 51 aPTT 51 plasma glucose 51 atorvastatin #mg 51 autoantibody positive 51 Kaplan Meier estimate 51 Adverse effects 51 mycophenolate mofetil MMF 51 hepatic fat 51 renal cysts 51 dosing cohort 51 IU ml 51 logistic regression model 51 Replikin Count 51 detectable HCV RNA 51 fatty infiltration 51 hsCRP levels 51 cGy 51 protein excretion 51 SGRQ 51 myocardial infarctions MIs 51 glomerular filtration rate 51 LVEF 51 nephrotoxicity 51 ALT AST 51 MADRS score 51 debulking surgery 51 mmHg systolic 51 anti Xa 51 CD3 + 51 pulmonary exacerbations 51 p = #.# [003] 51 neurodevelopmental outcomes 51 β blocker 51 antibody titers 51 ERK activation 51 distensibility 51 #mg/day [001] 51 Cmax 51 angiographic restenosis 51 #Gy 51 coronary calcification 51 μg L 51 abacavir lamivudine 51 NNRTI resistance 51 nodal metastasis 51 serum creatinine 51 neurodevelopmental outcome 51 ASCUS 51 systolic function 51 CVD mortality 51 neurologic outcomes 51 clodronate 51 timepoint 51 nocturnal hypoglycaemia 51 progression TTP 51 HIV HCV coinfected 51 ALT elevation 51 % CI #.#-#.# [007] 51 multivariable logistic regression 51 aminotransferases 51 HbA 1c 51 pentoxifylline 51 baseline Hb 51 BENICAR HCT 51 variant allele 51 rhGH 51 achieved ACR# 51 antithymocyte globulin 51 thyrotropin levels 51 Intraocular pressure 51 IU mL 51 nondiabetic patients 51 acarbose 51 serologically active patients 51 c reactive protein 51 virological response 51 advanced adenomas 51 lumen diameter 51 triglyceride concentration 51 milliliters mL 51 EBRT 51 airflow obstruction 50 lymphopenia 50 ug ml 50 cubic millimeter 50 elevated triglyceride levels 50 polyp recurrence 50 transgene expression 50 microliter 50 hyperphenylalaninemia HPA due 50 alteplase 50 Neutrophil 50 Neutropenia 50 paricalcitol 50 placebo dexamethasone 50 % CI #.#-#.# [006] 50 CC genotype 50 hypophosphatemia 50 mitoxantrone plus 50 creatinine clearance 50 adiponectin levels 50 plus medroxyprogesterone acetate 50 albuminuria 50 mg kg dose 50 mEq L 50 peripheral blood mononuclear 50 CK MB 50 symptomatic intracerebral hemorrhage 50 CD4 50 #dhTxB# 50 undetectable viral loads 50 plasma glucose concentrations 50 viraemia 50 nonobese 50 multiple logistic regression 50 mammographic density 50 CMV infection 50 Index CDAI 50 HbA1c levels 50 HBV DNA 50 certolizumab 50 calculated creatinine clearance 50 antiandrogens 50 4mg/kg 50 Kaplan Meier analysis 50 aromatase inhibitor therapy 50 mcg BID 50 KRAS mutant tumors 50 endoscopic gastric ulcers 50 dalteparin 50 receiving prophylactic anticoagulation 50 histologically confirmed 50 EQ 5D 50 serum ALT 50 sperm motility 50 plasma pharmacokinetics 50 FOLFIRI alone 50 triacylglycerol 50 multivariate logistic regression 50 SHBG levels 50 argatroban 50 PSA kinetics 50 tipranavir ritonavir 50 antiretroviral naïve 50 A1c levels 50 abnormal cytology 50 neurodevelopmental impairment 50 CD# + [002] 50 ng dL 50 NT proBNP concentrations 50 advanced adenoma 50 postprandial glycemia 50 tumor perfusion 50 serum folate 50 hepatic fibrosis 50 azacitidine 50 thyroid hormone levels 50 baseline A1C 50 ALT flares 50 Secondary endpoints include 50 TNF antagonist 50 transdermal estradiol 50 low dose Iluvien 50 elevated ALT 50 IELT 50 demonstrated clinically meaningful 50 #.#mmHg 50 nephrotoxic drugs 50 comparator arm 50 peak VO2 50 nonpregnant women 50 epithelial ovarian cancer 50 budesonide pMDI 50 R0 resection 50 pulmonary dysfunction 50 darunavir r 50 suboptimal adherence 50 fasting plasma glucose FPG 50 IV bisphosphonates 50 antihypertensive medications 50 RBC folate 50 pg mL 50 CPAP adherence 50 resected pancreatic cancer 50 CYP#D# genotype 50 androgen deprivation 50 EpCAM expression 50 mutated KRAS 50 atypical hyperplasia 50 SpCO 50 creatine kinase CK 50 #mg ATC 50 Endothelial function 50 pharmacodynamic PD 50 Scale EDSS score 50 urate levels 50 obstructive CAD 50 MELD score 50 oral antidiabetes 50 ApoB 50 sustained virological response 50 blood phenylalanine Phe 50 prednisone prednisolone 50 skeletal muscle mass 50 concentration Cmax 50 Tumor Response 50 doxorubicin cyclophosphamide 50 log# reduction 50 dose dependently 50 BARACLUDE ® 50 mediated dilation 49 logistic regression models 49 incontinence episodes 49 virologic failure 49 corneal curvature 49 subcutaneous dose 49 preoperative chemotherapy 49 virologic responses 49 Homocysteine levels 49 #q# deletion 49 IFN gamma 49 fractional shortening 49 Secondary efficacy endpoints 49 dosing frequency 49 Myelosuppression 49 GG genotype 49 airway hyper responsiveness 49 HBeAg negative 49 peginterferon alfa 49 immunosuppression therapy 49 gemcitabine cisplatin 49 analgesic medications 49 UGT#A# * 49 hyperoxia 49 prospectively stratified 49 mIU L 49 ABC/3TC 49 MoxDuo TM IR 49 sargramostim 49 virologic 49 acute GvHD 49 odds ratios ORs 49 CDI recurrence 49 bFGF 49 vincristine doxorubicin 49 ug dose 49 neurologic progression 49 gliclazide 49 comparator PI r 49 receiving ISENTRESS 49 mm Hg systolic 49 polytherapy 49 -#.# log# 49 acetaminophen codeine 49 gout flares 49 follicle stimulating hormone FSH 49 FOLFOX4 49 fosamprenavir 49 vWF 49 seropositive patients 49 prolactin elevation 49 CYP#D# inhibitor 49 CLL cells 49 urinary albumin excretion 49 daunorubicin 49 baseline neutrophil counts 49 ibandronate 49 carotid bruit 49 myocardial infarct size 49 fasting triglyceride levels 49 mCi m 2 49 ovarian carcinoma 49 NATRECOR ® 49 antioxidant intake 49 IgG antibody 49 meta regression 49 parasitemia 49 BSIs 49 CD4 cells 49 glycemia 49 virologic breakthrough 49 retinal thickness 49 μg mL 49 intravaginal ejaculatory latency 49 Psoriasis Area 49 VELCADE melphalan 49 aminotransferase ALT 49 chlamydial infection 49 cubic milliliter 49 morbidity mortality 49 fluvastatin 49 treatment naive genotype 49 cortical activation 49 Dietary fat 49 #mg dose [001] 49 hippocampal volumes 49 μg kg 49 low dose cytarabine 49 interferon ribavirin 49 nmol liter 49 HI titers 49 FOLPI 49 perioperative morbidity 49 Univariate 49 atherogenic lipids 49 recurrent glioblastoma multiforme 49 cEVR 49 ergocalciferol 49 viral load 49 lipid elevations 49 5-FU/LV 49 systolic blood pressures 49 aged ≥ 49 ICD therapy 49 oxcarbazepine 49 PBMCs 49 Folfox 49 PDE7B 49 Telintra 49 genital secretions 49 fragility fracture 49 macrolide antibiotic 49 mycophenolate mofetil 49 Univariate analysis 49 #mmHg [002] 49 vascular reactivity 49 vivo potency 49 CD4 lymphocyte count 49 obstructive coronary artery 49 candidemia 49 inotropic 49 left ventricular diastolic 49 renal function 49 procalcitonin 49 Thal Dex 49 corrected QT interval 49 % Confidence Interval 49 viremic 49 exogenous insulin 49 inhibitory concentration 49 colorectal polyp 49 asymptomatic carotid stenosis 49 FOLFOX6 49 receiving VICTRELIS 49 arterial stiffening 49 underwent resection 49 peak plasma concentrations 49 bivariate analyzes 49 UPPP 49 fumagillin nanoparticles 49 atherosclerotic lesion 49 MELD scores 49 logistic regression analyzes 48 nonexposed 48 hormone receptor negative 48 estramustine 48 dose dexamethasone 48 chronic HBV 48 restenosis reblockage 48 hypogonadal 48 mmol liter 48 mucosal healing 48 nitrotyrosine 48 CD4s 48 MAGE A3 ASCI 48 seminoma 48 lopinavir r arm 48 antiretroviral naive 48 HBV infections 48 plasma viremia 48 receiving APTIVUS r 48 liver enzymes ALT 48 -#.# log# copies mL 48 dose cyclophosphamide 48 danazol 48 RBC transfusion 48 atazanavir ritonavir 48 postoperative bleeding 48 platelet counts 48 adriamycin 48 OGTT 48 HCV RNA 48 indinavir 48 annualized relapse 48 Erythropoietic therapies may 48 CHADS2 48 pegfilgrastim 48 p# Shc 48 serum retinol 48 p = .# [002] 48 anthracycline therapy 48 plasma uric acid 48 shorter telomere length 48 platelet aggregation 48 mcg kg REBETOL 48 Triglyceride levels 48 VSMCs 48 dose cytarabine 48 psychosocial variables 48 pyrazinamide 48 Doxil ® 48 nucleotide substitutions 48 tapentadol ER 48 platelet count 48 buprenorphine implants 48 BCG vaccinated 48 NMIBC 48 bcr abl 48 pegIFN 48 VEGF expression 48 tamoxifen Nolvadex ® 48 HIV seroconversion 48 lobular involution 48 8mg/kg 48 amoxicillin clavulanate 48 bezafibrate 48 oral ibandronate 48 interindividual variability 48 balsalazide 48 weekly subcutaneous injections 48 colorectal carcinoma 48 testosterone secretion 48 esophageal acid 48 coagulation parameters 48 Provent Therapy 48 polyp detection 48 trastuzumab Herceptin ® 48 UPDRS scores 48 CD8 T cell 48 interquartile range 48 Flu Cy 48 Heritability 48 mg/m2 cohort 48 Multiple linear regression 48 URTI 48 CIMZIA TM certolizumab pegol 48 microlitre 48 proteinuria 48 reduce serum phosphate 48 pancreatic adenocarcinoma 48 coinfection 48 serum phosphorous 48 cardiac contractility 48 #.#/#.# mm Hg [003] 48 ug mL 48 epoetin alfa 48 CANCIDAS 48 neutralizing antibody 48 osteopenic 48 KRAS mutations 48 prostanoid 48 imipenem 48 plasma glucose levels 48 Index CDAI score 48 TNFalpha 48 LDL cholesterol concentrations 48 urine NGAL 48 selenium supplementation 48 APTIVUS r 48 HbF levels 48 distal colon cancer 48 teriflunomide 48 metastatic GIST 48 mU L 48 simvastatin #mg 48 5 Fluorouracil 48 mcg mL 48 K ras mutations 48 glucosylceramide 48 dose limiting toxicities 48 multivariate adjustment 48 Natalizumab 48 Zometa hazard 48 ritonavir boosted 48 flow mediated dilation 48 venous thromboembolic disease 48 nmol L 48 irbesartan 48 hsCRP 48 constipating effects 48 SLNB 48 HCV Genotype 48 incidence ≥ 48 nadroparin 48 hematological parameters 48 gemcitabine carboplatin 48 chlamydial 48 distal colon 48 MS relapses 48 hepatitis B immunoglobulin 48 Adjuvant chemotherapy 48 seroconversion 48 mammographic breast density 48 dopamine D2 receptor 48 plasma concentrations 48 spherical aberrations 48 mediated immunity 48 male hormones androgens 48 ß amyloid 48 LPV r 47 elevated LDL 47 glulisine 47 ribavirin therapy 47 CK # plasma concentrations 47 daytime somnolence 47 #mg dose [003] 47 severe renal impairment 47 IGFBP 3 47 ug kg 47 BRCA2 mutation carriers 47 diastolic BP 47 HBeAg negative patients 47 aminotransferase levels 47 HGPIN 47 IgG antibodies 47 amphetamine methamphetamine 47 CrCl 47 seroprotection 47 DAS# remission 47 adjunctive placebo 47 elevated hsCRP 47 #mg dose [002] 47 oral antidiabetic drugs 47 COPD exacerbations 47 #mg BID [003] 47 axillary node 47 underwent liver transplantation 47 micromoles 47 ARIXTRA 47 nadolol 47 OGG1 47 palivizumab 47 leukemia AML 47 fibrosis scarring 47 mRCC 47 + PH# 47 A1PI 47 C diff infections 47 spontaneous bowel movements 47 MULTAQ 47 Platinol ® cisplatin 47 mcg Albuferon 47 viral kinetics 47 impaired endothelial 47 cTnT levels 47 unplanned readmissions 47 unresectable tumors 47 antitumor effect 47 spontaneous preterm birth 47 undetectable viral load 47 febrile neutropenia 47 initiating antiretroviral therapy 47 detemir 47 tic severity 47 concomitant antibiotics 47 pharmacokinetic PK profile 47 #mg/m# [001] 47 K#N 47 #mg/kg [002] 47 Abeta# 47 oral FTY# 47 antidiabetic drug 47 saline placebo 47 loop diuretic 47 highly emetogenic 47 achieved CCyR 47 gastric pH 47 FluCAM 47 ascending dose 47 undergone splenectomy 47 #ng/ml 47 heavily pretreated 47 adult chronic ITP 47 generalized edema 47 oxidative stress markers 47 capillary permeability 47 neutropenic patients 47 bilateral oophorectomy 47 NSTE ACS 47 Immunohistochemical analysis 47 lymphatic cancers 47 log# 47 HCV antibody 47 mmol l 47 dexamethasone Decadron 47 response CCyR 47 dosage regimens 47 SCIg 47 eGFR 47 hemagglutination inhibition 47 neurocognitive deficits 47 cisplatin chemotherapy 47 Hb levels 47 mCRPC 47 hepatitis C genotype 47 BMPR2 47 noncancer 47 dehydroepiandrosterone sulfate 47 MDRD 47 NAMCS 47 MPRs 47 median PFS 47 extracapsular 47 antiplatelet medications 47 insulin detemir 47 atypical antipsychotic medications 47 creatinine 47 SIMPADICO 47 nucleotide analog 47 TMEM density 47 1cc 47 symptom exacerbation 47 hemorrhagic complications 47 LV hypertrophy 47 pharmacokinetics PK 47 aldosterone hormone 47 postprandial insulin 47 frequent awakenings 47 seroconverted 47 PANSS scores